Overview
Hereditary breast and ovarian cancer syndrome (HBOC) is a genetic condition primarily associated with pathogenic variants in the BRCA1 and BRCA2 genes, leading to significantly increased risks of breast and ovarian cancers. 15Diagnosis
Management
Special Populations
Key Recommendations
References
Showing 100 most recent of 203 indexed papers.
1 Jochum F, Dumas É, Salem JE, Ederhy S, Hamy AS, Lecointre L et al.. Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial. Clinical pharmacology and therapeutics 2026. link 2 Beekman MJ, Terra L, Bleiker EMA, Heemskerk-Gerritsen BAM, van Doorn HC, de Hullu JA et al.. Long-term outcomes of surgical menopause after risk-reducing salpingo-oophorectomy: results of the HARMOny study. Maturitas 2026. link 3 Zhong X, Luo S, Sheng Y, Chen L, Liu Y. A Rare Case of Trousseau Syndrome-Related Nonbacterial Thrombotic Endocarditis Caused by Mucinous Ovarian Carcinoma. Journal of clinical ultrasound : JCU 2026. link 4 Sánchez Cánovas M, López Robles J, García Verdejo FJ, Cacho Lavin D, Olivares H, Garrido Fernández A et al.. PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026. link 5 Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA et al.. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link 6 Cattaneo D, Ridolfo AL, Dalu D, Pruneri C, Giacomelli A, Cossu MV et al.. Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience. Expert opinion on drug metabolism & toxicology 2025. link 7 Yang C, Song X, Sun H, Chen X, Liu C, Chen M. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS). Expert opinion on drug safety 2025. link 8 Yang C, Song X, Sun H, Chen X, Liu C, Yang Y et al.. Peripheral Neuropathy in Patients With Ovarian Cancer Administrating Poly ADP-Ribose Polymerase Inhibitors: A Real-World Study Based on Bayesian Disproportionality Analysis of the US Food and Drug Administration Adverse Event Reporting System. Clinical therapeutics 2025. link 9 Ogura T, Shiraishi C. Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System. Expert opinion on drug safety 2025. link 10 Artigou H, Foka Tichoue H, Marques C, Charlotte F, Vion PA, Kas A et al.. Granulocyte Colony-Stimulating Factor-Associated Aortitis Unveiled by 18 F-FDG PET/CT. Clinical nuclear medicine 2025. link 11 Ward A, Dampali R, Wang W, Bertoni Sclavi S, Khalil HR, Touloumis A et al.. Risk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer. European journal of obstetrics, gynecology, and reproductive biology 2025. link 12 Peippo MH, Perkonoja K, Isoviita VM, Hynninen J, Lassila R, Carpén O. Association of clinical and laboratory variables with risk of venous thromboembolism in high-grade serous ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025. link 13 Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA et al.. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN 2024. link 14 Perez-Fidalgo JA, Gálvez-Montosa F, Guerra EM, Madariaga A, Manzano A, Martin-Lorente C et al.. SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024. link 15 McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM et al.. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. European journal of human genetics : EJHG 2024. link 16 Levin G, Brezinov Y, Meyer R, Oranim N. Gynecologic oncology top-cited articles: an international analysis. Minerva obstetrics and gynecology 2024. link 17 Mathew AT, Jain B, Patel TA, Hammond A, Dee EC, Chino F. Trends in Location of Death for Individuals With Ovarian Cancer in the United States. Obstetrics and gynecology 2024. link 18 Ross TL, Neale RE, Na R, Webb PM. Vitamin D status during and after treatment and ovarian cancer survival. Cancer causes & control : CCC 2024. link 19 Chen J, Lai YL, Lee JK, Lin HW, Sun WZ, Chen YL et al.. Does the diagnostic timing of cancer-associated thromboembolism influence the survival outcome in ovarian cancer patients?. Journal of the Formosan Medical Association = Taiwan yi zhi 2024. link 20 Shim H, Lee YJ, Kim JH, Lim MC, Lee DE, Park SY et al.. Preoperative laboratory parameters associated with deep vein thrombosis in patients with ovarian cancer: retrospective analysis of 3,147 patients in a single institute. Journal of gynecologic oncology 2024. link 21 Sánchez-Heras AB, Ramon Y Cajal T, Pineda M, Aguirre E, Graña B, Chirivella I et al.. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023. link 22 Wilson CM. The Integration of Both Practice and Research Into Gynecologic Oncology Nursing. Nursing for women's health 2023. link 23 Baek AE. Interferon with ovarian cancer. Science signaling 2023. link 24 Burke W, Barkley J, Barrows E, Brooks R, Gecsi K, Huber-Keener K et al.. Executive Summary of the Ovarian Cancer Evidence Review Conference. Obstetrics and gynecology 2023. link 25 Mullins MA, Ruterbusch J, Cote ML, Uppal S, Wallner LP. Trends in hospice referral timing and location among individuals dying of ovarian cancer: persistence of missed opportunities. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023. link 26 Gaughan S, Williams M. The holistic management of malignant bowel obstruction in women with advanced ovarian cancer at end of life. British journal of nursing (Mark Allen Publishing) 2023. link 27 Woo S, Nah S, Kim G, Han S. Fracture of an Intravenous Cannula in the Hand: A Case Report. Journal of emergency nursing 2023. link 28 Wiegers HMG, Schaafsma M, Guman NAM, Zelisse HS, Mulder FI, Middeldorp S et al.. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis. Journal of thrombosis and haemostasis : JTH 2023. link 29 D'Arrigo S, Annetta MG, Musarò A, Distefano M, Pittiruti M. Secondary malposition of a PICC-port due to heavy physical exercise: A case report. The journal of vascular access 2023. link 30 Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M et al.. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66. BJOG : an international journal of obstetrics and gynaecology 2022. link 31 Reyna ÁG, Griffin GK. Selfish antibodies target auto-antigens in cancer. Science immunology 2022. link 32 . Tissue-Resident Memory-like Lymphocytes Demonstrate Effector Activity in Ovarian Cancer. Cancer discovery 2022. link 33 Gilks CB, Selinger CI, Davidson B, Köbel M, Ledermann JA, Lim D et al.. Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022. link 34 Mullins MA, Uppal S, Ruterbusch JJ, Cote ML, Clarke P, Wallner LP. Physician Influence on Variation in Receipt of Aggressive End-of-Life Care Among Women Dying of Ovarian Cancer. JCO oncology practice 2022. link 35 Smith S, Lambert P, Nachtigal MW, Altman AD. Perioperative Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Using Four Different Data Collection Methods: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2022. link 36 Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA et al.. SEOM clinical guideline in ovarian cancer (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021. link 37 Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A et al.. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2021. link 38 Athey RA, Macdonald MC, Jha S. Stage of ovarian cancer at diagnosis. Does presentation as an emergency make a difference?. European journal of obstetrics, gynecology, and reproductive biology 2021. link 39 Hirayama T, Inayama Y, Odajima S, Yamanaka A, Sekine M, Terao Y et al.. A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk-reducing surgery for hereditary breast and ovarian cancer. The journal of obstetrics and gynaecology research 2021. link 40 Mullins MA, Ruterbusch JJ, Clarke P, Uppal S, Wallner LP, Cote ML. Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer. Cancer 2021. link 41 Mullins MA, Ruterbusch JJ, Clarke P, Uppal S, Cote ML, Wallner LP. Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. Gynecologic oncology 2021. link 42 Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M et al.. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021. link 43 Matanes E, Boulus S, Lauterbach R, Matanis J, Reiss A, Amit A. Raynaud's phenomenon as a presenting manifestation of ovarian cancer: A case report. The journal of obstetrics and gynaecology research 2021. link 44 Tavares V, Pinto R, Assis J, Coelho S, Brandão M, Alves S et al.. Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients. The pharmacogenomics journal 2021. link 45 van Bommel MHD, de Jong MA, Steenbeek MP, Bots ML, van Westerop LLM, Hopman MTE et al.. No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Journal of cardiology 2021. link 46 Vorobev A, Makatsariya A, Bitsadze V, Khizroeva J, Solopova A. Unusual thrombosis or pregnancy complications associated to ovarian cancers: two clinical cases. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2021. link 47 Noto H. Dawn of a new era of diabeto-oncology. Journal of diabetes investigation 2020. link 48 López-Salazar J, Ramírez-Tirado LA, Gómez-Contreras N, Pacheco-Bravo I, Cortés E, Gallardo D et al.. Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. Internal medicine journal 2020. link 49 Norris S, Papillon-Smith J, Gagnon LH, Jacobson M, Sobel M, Shore EM. Effect of a Surgical Teaching Video on Resident Performance of a Laparoscopic Salpingo-oophorectomy: A Randomized Controlled Trial. Journal of minimally invasive gynecology 2020. link 50 Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Mikami M et al.. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma. Journal of gynecologic oncology 2020. link 51 Gavrielides MA, Miller M, Hagemann IS, Abdelal H, Alipour Z, Chen JF et al.. Clinical Decision Support for Ovarian Carcinoma Subtype Classification: A Pilot Observer Study With Pathology Trainees. Archives of pathology & laboratory medicine 2020. link 52 Jørgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. Journal of geriatric oncology 2020. link 53 Pivetta E, Spessotto P. Multispectral imaging technology: Visualize, analyze, phenotyping, and quantify immune cells in situ. The International journal of biological markers 2020. link 54 L'Espérance K, Datta GD, Qureshi S, Koushik A. Vitamin D Exposure and Ovarian Cancer Risk and Prognosis. International journal of environmental research and public health 2020. link 55 Fresard ME, Erices R, Bravo ML, Cuello M, Owen GI, Ibanez C et al.. Multi-Objective Optimization for Personalized Prediction of Venous Thromboembolism in Ovarian Cancer Patients. IEEE journal of biomedical and health informatics 2020. link 56 Narasimhulu DM, Bews KA, Hanson KT, Chang YH, Dowdy SC, Cliby WA. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer. Gynecologic oncology 2020. link 57 . BRCA Exchange Launches. Cancer discovery 2019. link 58 . Immunotherapy Activates Unexpected Cell Death Mechanism. Cancer discovery 2019. link 59 Cham S, Chen L, St Clair CM, Hou JY, Tergas AI, Melamed A et al.. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. American journal of obstetrics and gynecology 2019. link 60 Filippova OT, Chi DS, Long Roche K, Sonoda Y, Zivanovic O, Gardner GJ et al.. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. Gynecologic oncology 2019. link 61 Oldak S, Ioannou S, Kamath P, Huang M, George S, Slomovitz B et al.. Polypharmacy in Patients with Ovarian Cancer. The oncologist 2019. link 62 Lu Z, Kamat K, Johnson BP, Yin CC, Scholler N, Abbott KL. Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms. Scientific reports 2019. link 63 Wagner BE, Langstraat CL, McGree ME, Weaver AL, Sarangi S, Mokri B et al.. Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. Gynecologic oncology 2019. link 64 Kuroda N, Hiramatsu H, Mori M, Tanaka T. Mechanical Thrombectomy for Trousseau Syndrome in a Terminally Ill Cancer Patient. Journal of pain and symptom management 2019. link 65 Urban RR, He H, Alfonso R, Hardesty MM, Goff BA. The end of life costs for Medicare patients with advanced ovarian cancer. Gynecologic oncology 2018. link 66 Chiang JK, Hsu CS, Lin CW, Kao YH. End-of-Life Care for Patients With Advanced Ovarian Cancer Is Aggressive Despite Hospice Intervention: A Population-Based Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2018. link 67 Miller D, Nevadunsky N. Palliative Care and Symptom Management for Women with Advanced Ovarian Cancer. Hematology/oncology clinics of North America 2018. link 68 Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. British journal of haematology 2017. link 69 . Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstetrics and gynecology 2017. link 70 . Committee Opinion No. 716 Summary: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstetrics and gynecology 2017. link 71 Satoh T, Takamatsu K, Takeshima N, Kobayashi H, Aoki D, Suzuki N. Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan. The journal of obstetrics and gynaecology research 2017. link 72 Mikami M, Nagase S, Yamagami W, Ushijma K, Tashiro H, Katabuchi H. Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology. Journal of gynecologic oncology 2017. link 73 Ng KL, Nawawi O, Lim BK, Htun TH, Dublin N, Razack AH. Antegrade repositioning of Memokath stent in malignant ureteroileal anastomotic stricture. Asian journal of surgery 2017. link 74 Kommoss S, Kommoss F, Diebold J, Lax S, Schmidt D, Staebler A et al.. Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review. British journal of cancer 2017. link 75 Segev Y, Segev L, Schmidt M, Auslender R, Lavie O. Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review. Archives of gynecology and obstetrics 2017. link 76 Swier N, Versteeg HH. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Thrombosis research 2017. link 77 Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP et al.. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017. link 78 Słodkowska J, Cierniak S, Patera J, Kopik J, Baranowski W, Markiewicz T et al.. Functional Assessment of Synoptic Pathology Reporting for Ovarian Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology 2016. link 79 Ghosh A, Ghartimagar D, Thapa S, Sathian B, Narasimhan R, Talwar OP. Ovarian Tumors: Pattern of Histomorphological Types- A 10 Years Study in a Tertiary Referral Center and Review of Literature. Kathmandu University medical journal (KUMJ) 2016. link 80 Hashmi AA, Hussain ZF, Bhagwani AR, Edhi MM, Faridi N, Hussain SD et al.. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective. BMC research notes 2016. link 81 Woopen H, Richter R, Ismaeel F, Chekerov R, Roots I, Siepmann T et al.. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecologic oncology 2016. link 82 Heath OM, van Beekhuizen HJ, Nama V, Kolomainen D, Nobbenhuis MAE, Ind TEJ et al.. Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thrombosis research 2016. link 83 McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H et al.. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015. link 84 de la Cruz M, Reddy A, Bruera E. A palliative care intervention for pain refractory to a percutaneous cordotomy. Palliative & supportive care 2015. link 85 Daniele A, Ferrero A, Fuso L, Mineccia M, Porcellana V, Vassallo D et al.. Palliative care in patients with ovarian cancer and bowel obstruction. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2015. link 86 Mohapatra S, Saxena A, Gandhi G, Koner BC, Singh T, Ray PC. Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015. link 87 Schlumbrecht MP, Hehr K. Cisplatin-induced bradycardia and the importance of the QT interval. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2015. link 88 Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M et al.. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. link 89 Yuan L, Liu X. Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. Molecular medicine reports 2015. link 90 . Ovarian tumors metastasize in blood. Cancer discovery 2014. link 91 Rodríguez-Ayala G, Romaguera J, López M, Ortiz AP. Ovarian cancer screening practices of obstetricians and gynecologists in puerto rico. BioMed research international 2014. link 92 Tsubamoto H, Ito Y, Kanazawa R, Wada R, Hosoda Y, Honda O et al.. Benefit of palliative chemotherapy and hospice enrollment in late-stage ovarian cancer patients. The journal of obstetrics and gynaecology research 2014. link 93 Brown AJ, Sun CC, Prescott LS, Taylor JS, Ramondetta LM, Bodurka DC. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecologic oncology 2014. link 94 Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V et al.. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. The Journal of biological chemistry 2014. link 95 . Bevacizumab and relapsed ovarian cancer: too many serious and life-threatening adverse effects. Prescrire international 2013. link 96 Meaney-Delman D, Bellcross CA. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. Obstetrics and gynecology clinics of North America 2013. link 97 Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S et al.. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013. link 98 Yokota SJ, Facciponte JG, Kelleher RJ, Shultz LD, Loyall JL, Parsons RR et al.. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer immunity 2013. link 99 Clark RM, Growdon WB, Wiechert A, Boruta D, Del Carmen M, Goodman AK et al.. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma. Gynecologic oncology 2013. link 100 Dieplinger B, Egger M, Gabriel C, Poelz W, Morandell E, Seeber B et al.. Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clinica chimica acta; international journal of clinical chemistry 2013. link